Add New Post

The titles are words of warning from a North Carolina woman in the Moderna COVID-19 vaccine study who is in her 50s..

“If this proves to work, people are going to have to toughen up,” she said. “The first dose is no big deal. And then the second dose will definitely put you down for the day for sure. … You will need to take a day off after the second dose.”

She was quoted in various news media, including this CNBC article about the challenges of the upcoming COVID-19 vaccines..

Some of the money quotes for future posterity:

Public health officials and drugmakers need to warn people that coronavirus vaccine shots may have some rough side effects so they know what to expect and aren’t scared away from getting the second dose, doctors urged during a meeting Monday with CDC advisors.

AND

“We really need to make patients aware that this is not going to be a walk in the park,” Fryhofer said during a virtual meeting with the Advisory Committee on Immunization Practices, or ACIP, an outside group of medical experts that advise the CDC. She is also a liaison to the committee. “They are going to know they had a vaccine. They are probably not going to feel wonderful. But they’ve got to come back for that second dose.”

Will you be contagious?!

“If they have to miss 14 days of work, that’s a huge amount to miss,” said Lee, who is a member of the ACIP, told the CDC. “I think we do have to think about that the vaccine itself. While there may be some short term work loss issues, I do think that has to be balanced with the risk of getting an infection.

It’s coming!

Federal agencies are already sending vaccination plans around to staff. Five agencies have started telling employees they could receive Pfizer’s or Moderna’s Covid-19 vaccine in as little as eight weeks, a person with firsthand knowledge of those plans told CNBC on Friday.

There soaring stock markets the other day with press releases that vaccines were 90% or 95% effective!

But reality is setting in..

AstraZeneca said Monday that its coronavirus vaccine reduced the risk of symptomatic Covid-19 by an average of 70.4%, according to an interim analysis of large Phase 3 trials conducted in the United Kingdom and Brazil.

DEVELOPING..